Q4 FY2025 · ended Dec 31, 2025 · Revenue $838,000, -61.6% YoY · Filed Mar 3, 2026
Prime Medicine, Inc. (PRME) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$41.1 million. As of Jun 30, 2026 it held $95.1 million in cash and investments and $112.5 million in total debt.
Revenue
$838,000
-61.6% vs year-ago quarter
Net income
$-42.11M
+19.9% vs year-ago quarter
Operating cash flow
$-41.05M
+0.9% vs year-ago quarter
Free cash flow
$-41.09M
+4.4% vs year-ago quarter
EPS
$-0.24
+41.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
181.38M
+34.8% vs year-ago quarter
Net cash
$-17.41M
Q2 FY2026
Operating margin
-5800.5%
Q4 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PRME (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1894562
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $838,000 | $1.2M | $1.1M |
| Operating income | -$43.3M | -$50.7M | -$48.6M | -$54.0M | -$53.4M |
| Net income | -$42.1M | -$49.1M | -$46.1M | -$50.6M | -$52.6M |
| Diluted EPS | -$0.24 | -$0.28 | -$0.26 | -$0.32 | -$0.41 |
| Operating cash flow | -$41.0M | -$42.7M | -$37.3M | -$35.0M | -$41.4M |
| Free cash flow | -$41.1M | -$42.9M | -$37.5M | -$35.3M | -$43.0M |
| Total assets | $249.0M | $294.7M | $342.7M | $385.0M | $279.0M |
| Total liabilities | $209.2M | $218.0M | $221.9M | $223.2M | $218.1M |
| Stockholders' equity | $39.8M | $76.7M | $120.9M | $161.8M | $60.9M |
| Cash and investments | $95.1M | $135.5M | $177.7M | $208.4M | $98.3M |
| Total debt | $112.5M | $114.5M | $116.4M | $118.1M | $119.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 298 Prime Medicine, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.